Follow us:

科研产品

  • 基因表达PCR芯片
  • 体细胞突变PCR芯片
  • 拷贝数变化PCR芯片
  • 基因分型PCR芯片
  • 蛋白表达抗体芯片
  • 蛋白磷酸化抗体芯片
  • 蛋白质相互作用芯片
  • 引物和探针
  • 常规分子生物学试剂

  • 临床产品

  • 个性化用药
  • 易感基因检测
  • 生物标志物试剂盒

  • > 产品目录 > 科研产品 > 体细胞突变PCR芯片 > ErbB2/HER2/neu通路突变PCR芯片
    ERBB2,也被称为HER2, neu, 是一种细胞膜表面结合的受体酪氨酸激酶,常参与细胞信号转导途径,调节细胞增殖和分化。ERBB2是ERBB表皮生长因子受体家族成员之一。近期研究显示,ERBB2激酶结构域体细胞突变可出现在多种肿瘤中,如肺腺癌,乳腺癌,胃癌以及结直肠癌等,提示ERBB2自身突变或其下游基因突变对ERBB2通路的影响可能与肿瘤的发生相关。
    ErbB2/HER2/neu通路突变PCR芯片
    ERBB2,也被称为HER2, neu, 是一种细胞膜表面结合的受体酪氨酸激酶,常参与细胞信号转导途径,调节细胞增殖和分化。ERBB2是ERBB表皮生长因子受体家族成员之一。近期研究显示,ERBB2激酶结构域体细胞突变可出现在多种肿瘤中,如肺腺癌,乳腺癌,胃癌以及结直肠癌等,提示ERBB2自身突变或其下游基因突变对ERBB2通路的影响可能与肿瘤的发生相关。
     
    人ERBB2通路体细胞突变PCR芯片适用于ErbB2/HER2/neu基因及其通路下游关键基因的突变检测,包括RAS-MAPK和PI3K通路。利用单个或多个体细胞突变信息检测关键信号通路异常已被广泛应用于临床研究。例如: EGFR和KRAS基因突变能够预测靶向该位点的药物治疗响应。ERBB2通路体细胞突变PCR芯片覆盖广泛,适用于ERBB2通路突变检测,并有望为临床相关疾病提供潜在药物治疗靶点。该芯片包含ERBB2通路中85个最常见并具有重要功能和生理学意义的突变位点。突变位点主要由多种体细胞突变数据库以及经同行评阅的科学文献筛选得到。该芯片操作简单,只需借助real-time PCR仪即可完成,应用广泛。
     
    体细胞突变PCR芯片仅适用于分子生物学研究,不适用疾病的临床诊断及治疗。
     
    Assay functional annotations
    ERBB2/HER2/neu gene:
    11 mutation assays are included in this panel to provide comprehensive coverage for the most frequently identified ERBB2 activating mutations. These mutations cluster in the ERBB2 kinase domain region.
    AKT gene:
    The mutation assays detects the best known AKT1 mutation, c.49G>A, p.E17K. This is a PH domain mutation that results in constitutive targeting of AKT1 to plasma membrane.
    BRAF gene:
    Two classes of mutation assays are included. One class covers mutations that lead to increased BRAF kinase activity, such as the p.L597 and p.V600 mutations. The other class detects mutations that lead to impaired kinase activity, such as the p.G464V, p.G466V and p.G469A mutations.
    KRAS gene:
    17 KRAS mutation assays provide comprehensive analysis capacity for the most frequently occurring mutations in KRAS codon positions 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RASGAP. The p.L19F and p.Q22K mutation assays are also included.
    HRAS gene:
    Similar to KRAS mutation assays, the 13 HRAS mutation assays on this panel aim to comprehensively cover the most important HRAS mutations identified in cancers at codon 12, 13, and 61 positions.
    NRAS gene:
    12 NRAS mutation assays are included on the panel to cover codon positions 12, 13, and 61, as well as mutation p.A18T.
    MEK1 gene:
    4 assays for mutations with verified clinical significance in cancer were included on the panel. These mutations cluster in MEK1 N-terminal negative regulatory domain and an adjacent domain, and are all activating mutations (i.e. lead to up-regulated intrinsic MEK1 kinase activity).
    PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) gene:
    The mutation assays covered on this panel can detect 8 of the most frequently occurring PIK3CA mutations that belong to three classes: p.H1047 mutations, which are activating, kinase domain mutations; mutations in the P539-E545 region, which are helical domain mutations that mimic activation by growth factors; and a p.N1068fs*4 early stop codon mutation which is caused by insertion.
    PTEN gene:
    Included on the panel are 10 of the most commonly detected PTEN loss-of-function mutations that are due to either truncation (p.K6fs*4, p.R130*, p.R130fs*4, p.R233*, p.P248fs*5, and p.V317fs*3) or point mutation-caused phosphatase inactivation (p.R130 and p.R173 mutations).
     
     

    规格:85个位点/array   1sample/array
    可以检测低至0.1%的体细胞突变


    更多了解产品和解决方案>>
    美好杏园你我共创